Prison release opioid treatment: does choice of injection matter?
NCT ID NCT06880718
First seen May 16, 2026 · Last updated May 16, 2026
Summary
This study tests two long-acting buprenorphine injections (Sublocade and Brixadi) to see which helps people with opioid use disorder stay in treatment after leaving prison. About 60 participants will either choose their preferred shot or be randomly assigned one. Researchers will track treatment retention, opioid use, and side effects for six months after release.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for OPIOID USE DISORDER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Rhode Island Department of Corrections
RECRUITINGCranston, Rhode Island, 02920, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.